SUNHO
BIOPHARMACEUTICAL (CHINA) CO. LTD

Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

APPOINTMENT OF INDEPENDENT INTERNAL CONTROL CONSULTANT AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements (the "**Announcements**", each an "**Announcement**") of the Company dated March 27, 2026, March 30, 2026, April 1, 2026, April 21, 2026, April 27, 2026, May 3, 2026 and June 29, 2026 in relation to, among other things, the delay in publication of 2025 Annual Results, the suspension of trading in the Shares, the Resumption Guidance and the quarterly update on status of resumption. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

APPOINTMENT OF INDEPENDENT INTERNAL CONTROL CONSULTANT

As mentioned in the Announcement dated May 3, 2026, the Stock Exchange sets out its requests in the Resumption Guidance for the Company to, among others, engage an independent internal control consultant (the "**Independent IC Consultant**") to conduct an independent internal control review (the "**Independent IC Review**") and demonstrate that: (i) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (ii) the internal controls of the Company are adequate and effective to serve their purposes and enable the Company to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, cash management, disclosure and compliance relating to notifiable and connected transactions, and disclosure of material information.

On August 4, 2026, based on the recommendation of the Audit Committee, the Company engaged Cheng & Cheng Risk Advisory Services Limited as the Independent IC Consultant to conduct the Independent IC Review. The Independent IC Review is proposed to be conducted in three main phases: (i) a preliminary assessment to gain an understanding of the Group's existing internal control framework; (ii) an in-depth review to identify control deficiencies and recommend remedial measures; and (iii) a follow-up review to evaluate the effectiveness of the remediation measures implemented. The Independent IC Review will cover the Group's internal control systems across all key areas, including financial reporting, procurement, sales, cash management, prepayment management, research and development, outsourcing, contract management, Listing Rules compliance, and other material operational and governance processes.

As of the date of this announcement, the Independent IC Review is ongoing. Further announcement(s) will be made by the Company to keep the Shareholders and potential investors of the Company informed of the progress and any material developments or key findings and views regarding the Independent IC Review as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, August 4, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.